In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acorda Therapeutics Inc.

www.acorda.com

Latest From Acorda Therapeutics Inc.

US ‘Blocking-Patent’ Doctrine Comes Under Attack

A US court doctrine that has invalidated patents covering major drugs such as Ampyra and Restasis is under attack from petitions to the US Supreme Court filed by Acorda and Allergan.
Intellectual Property United States

Kyowa Kirin Presses On With Parkinson's Prospect In US As Successor Readied

Some 12 years after first NDA submission, Kyowa Hakko Kirin tries again to secure US approval for troubled Parkinson's drug, but some analysts remain unsure of commercial potential and the company itself is progressing a successor.

United States Business Strategies

Rovi and Recordati Deemed Top Picks By Analyst

The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.

Market Intelligence Europe

While You Were Out: News In Brief

Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions. 
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register